A share price of Neurocrine Biosciences, Inc [NBIX] is currently trading at $131.24, down -2.88%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NBIX shares have gain 1.94% over the last week, with a monthly amount glided 4.98%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neurocrine Biosciences, Inc [NASDAQ: NBIX] stock has seen the most recent analyst activity on July 10, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $182. Previously, Needham upgraded its rating to Buy on April 15, 2025, and kept the price target unchanged to $138. On April 14, 2025, upgrade upgraded it’s rating to Outperform but maintained its price target of $137 on the stock. Deutsche Bank started tracking the stock assigning a Hold rating and suggested a price target of $138 on February 11, 2025. Piper Sandler upgraded its rating to Overweight for this stock on August 29, 2024, and upped its price target to $159. In a note dated April 24, 2024, Wells Fargo upgraded an Overweight rating on this stock and boosted its target price from $140 to $170.
Neurocrine Biosciences, Inc experienced fluctuations in its stock price throughout the past year between $84.23 and $157.98. Currently, Wall Street analysts expect the stock to reach $158.67 within the next 12 months. Neurocrine Biosciences, Inc [NASDAQ: NBIX] shares were valued at $131.24 at the most recent close of the market. An investor can expect a potential return of 20.9% based on the average NBIX price forecast.
Analyzing the NBIX fundamentals
Trailing Twelve Months sales for Neurocrine Biosciences, Inc [NASDAQ:NBIX] were 2.41B which represents 11.12% growth. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.21%, Pretax Profit Margin comes in at 0.19%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.12 and Total Capital is 0.16. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 129.50 points at the first support level, and at 127.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 134.62, and for the 2nd resistance point, it is at 137.99.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Neurocrine Biosciences, Inc [NASDAQ:NBIX] is 3.13. Also, the Quick Ratio is 3.02, while the Cash Ratio stands at 0.37. Considering the valuation of this stock, the price to sales ratio is 5.38, the price to book ratio is 5.12 and price to earnings (TTM) ratio is 44.50.
Transactions by insiders
Recent insider trading involved Delaet Ingrid, Chief Regulatory Officer, that happened on Jul 10 ’25 when 457.0 shares were sold. Chief Scientific Officer, Onyia Jude completed a deal on Jul 09 ’25 to sell 59819.0 shares. Meanwhile, Officer INGRID DELAET bought 457.0 shares on Jul 10 ’25.
